Vaccine preventable diseases evidence certification form To be completed by the applicant's treating medical practitioner, registered nurse, or occupational health provider

Applicant surname:			Practice stamp or facility name and address:	
First name:				
Address:				
Phone number: D		Date of birth:		
Email:				
Job Reference				
Health Professional name:		Designation:		
Health Professi	ional signature:	Provider No.: (if applicable)		
Disease	Evidence of vaccination	Documented serology	Other acceptable	QH use
		results	evidence	only
Measles,	□ Two documented doses of	□ positive IgG for each of	□ Birth date before 1966	Compliant
Mumps, and	Measles, mumps and	measles, mumps, and	R	(circle):
Rubella	rubella(MMR)vaccine at least one month apart			Yes / No
	Date of dose 1:	Source: QML	□ Partial course of MMR	OR
		□ SNP	vaccine ²	Partially
	//	Qld Health AUSLAB	Date of dose 1:	compliant
	Date of dose 2:	□ Other:	/ /	
	//			
Pertussis	□ Documented history of	Not applicable	Not applicable	Compliant
	one adult dose of dTpa within the past ten years			(circle):
				Yes / No
	Date of dose:			
	//			
Varicella	Documented history of	□ Positive IgG for varicella ¹	Documented history of	Compliant
	age appropriate course of	Source: QML	physician-diagnosed	(circle):
	varicella vaccination ³ (including zoster)		chickenpox or shingles ⁴	Yes / No
		□ Qld Health AUSLAB		OR
	Date of dose 1:		Partial course of varicella vaccine	□ Partially
	//	□ Other:	(including zoster) ⁵	compliant
	Date of dose 2*:		Date of dose 1:	
	//			
	(*if course is initiated after		//	
	age 14).			



Hepatitis B	 Documented history of two or three doses for age appropriate course of hepatitis B vaccine⁶ Date of dose 1: 	□ Anti-HBs greater than or equal to 10 IU/mL ⁷ Source:□ QML R □ SNP 0	 Documented evidence that the individual is not susceptible to hepatitis B⁸ 	Compliant (circle): Yes / No <i>OR</i>
	/	□ Qld Health AUSLAB	□ Partial course of	□ Partially compliant
	Date of dose 2: // Date of dose 3:	□ Other:	Hepatitis B vaccine ⁹ Date of dose 1: //	
	//		Date of dose 2: //	

Privacy Notice

Personal information collected by Queensland Health is handled in accordance with the *Information Privacy Act 2009*. Queensland Health is collecting personal information in accordance with the *Information Privacy Act 2009* in order to meet its obligations to provide a safe workplace. All personal information will be securely stored and only accessible by authorised Queensland Health staff.

Your personal information will not be disclosed to any other third parties without consent, unless required by law. If you choose not to provide your personal information, you will not meet the condition of employment.

For information about how Queensland Health protects your personal information, or to learn about your right to access your own personal information, please see our website at <u>www.health.qld.gov.au</u>

Consent

I consent to the recruitment panel/human resources department giving personal information in this form to other areas within the Queensland public sector health system (including the Department of Health and Hospital and Health Services) for workforce planning and for outbreak management planning and response. This may include line managers and infection control units.

Applicant please complete:

Name: ___

Signature:___

Australian Immunisation Handbook 10th Edition (updated June 2015) brand names of vaccines are as follows:

Hepatitis B

Brand names of hepatitis B vaccines are:

- H-B-Vax II (adult or paediatric formulation)
- Engerix-B (adult or paediatric formulation)

Brand names of combination vaccines containing hepatitis B vaccine are:

 Infanrix hexa (diphtheria, tetanus, pertussis, Haemophilus influenzae type b, Hepatitis B, polio) Twinrix/Twinrix Junior (hepatitis A, hepatitis B

- ComVax (Haemophilus influenza type B, hepatitis B)¹⁰
- Infanrix hep B (diphtheria , tetanus , pertussis, acellular, hep B)¹⁰

Measles, Mumps, Rubella

Brand names of MMR vaccine are:

- M-M-R-II
- Priorix

Vaccines that contain measles, mumps, rubella and varicella (chickenpox) vaccines are:

Date:

- Priorix-tetra
- ProQuad

Varicella

- Varilrix
- Varivax

Brand names of combination vaccine containing varicella vaccine are:

- Priorix-tetra
- ProQuad

Brand name of zoster vaccine:

Zostavax.

Footnotes and further information:

- 1. Positive IgG (Immunoglobulin G) indicates evidence of serological immunity, which may result from either natural infection or immunisation.
- Pre offer of employment requires minimum of one dose of Measles, mumps, rubella (MMR) vaccine course and second dose to be administered within three months of commencement. The prospective worker will be required to commit to completing the full course.
- 3. Two doses of varicella vaccine at least one month apart (evidence of one dose is sufficient if the person received their first dose before 14 years of age).
- Letters from medical practitioners or other vaccine service providers should state the date chickenpox or shingles was diagnosed and should be on practice/facility letterhead, signed by the provider/practitioner including professional designation and service provider number (if applicable).
- Pre offer of employment requires minimum of one dose of Varicella (chicken pox) vaccine course and second dose (if required) to be administered within three months of commencement. The prospective worker will be required to commit to completing the full course.
- 6. Hepatitis B vaccine is usually given as a 3 dose course with 1 month minimum interval between 1st and 2nd dose, 2 months minimum interval between 2nd and 3rd dose and 4 months minimum interval between 1st and 3rd dose. For adolescents between the ages of 11-15 hepatitis B vaccine may be given as a two dose course, with the two doses 4-6 months apart.
- Anti-HBs (hepatitis B surface antibody) greater than or equal to 10 IU/mL indicates immunity. If the result is less than 10 IU/mL (<10 IU/mL), this indicates lack of immunity.
- 8. Documented evidence that an individual is not susceptible to hepatitis B infection may include serology testing indicating a hepatitis B core antibody (Anti-HBc /HBcAb), or a documented history of past hepatitis B infection. Prospective workers (including students and volunteers) who are hepatitis B antigen positive do not have to disclose their hepatitis B infection status unless they perform exposure-prone procedures (see *Guideline for the management of Human Immunodeficiency Virus (HIV), hepatitis B virus,* and hepatitis C virus infected healthcare workers).

- Pre offer of employment requires minimum of two doses of Hepatitis B vaccine course and third dose to be administered within six months of commencement. The prospective worker will be required to commit to completing the full course.
- ComVax and Infanrix hexa are brand names of vaccine not in the updated Australian Immunisation Handbook 10th Edition (updated June 2015). These are vaccines that were included in previous immunisation schedules. Internationally administered vaccine may have a different brand name.

Tuberculosis Risk Assessment Form for STUDENTS

Student Information	
Given name/s:	
Student Number:	
Education Provider:	
Course/Module of Study:	
Email:	

Instructions:

- All students must be assessed for their risk of tuberculosis (TB) before commencing a clinical placement.
- Please complete the following questions and return the completed form and any additional documentation (if required) to your Education Provider Placement Coordinator prior to commencement of placement.
- Retain a copy of this form and any relevant documentation to take with you if any further assessment is required.
- If you do not understand the questions please complete this form with your doctor's help.
- Further testing and/or health assessment may be required, depending on your personal circumstances.

Privacy Notice: Personal information about students collected by Queensland Health is handled in accordance with the Information Privacy Act 2009. Queensland Health is collecting your personal information to meet its obligations to protect the public and to provide a safe workplace as per the current Tuberculosis Control QH-Health Service Directive 2018 and the Public Health Act 2005 and Public Health Regulation 2018. All personal information will be securely stored and reasonable steps will be taken to keep it accurate, complete and up-to-date. Personal information recorded on this form will not be disclosed to Queensland Health officers or third parties unless the disclosure is authorised or required by or under law. If you choose not to provide your personal information, you will not meet the condition of placement. For further information about how Queensland Health protects your personal information, or to learn about your right to access your own personal information, please see our website at www.health.gld.gov.au.

Part A: Signs of active TB - Do you currently have any of the following symptoms?		
1. Cough for more than 2 weeks (not related to an existing diagnosis or condition)	🗆 No 🗖 Yes	
2. Unexplained fever for more than 1 week		
3. Recent unexplained weight loss	🗆 No 🗖 Yes	
4. Coughing up blood	□ No □ Yes	
5. Excessive sweating during the night for more than 1 week		
If you have answered YES to any questions from Part A:		
 Make an urgent appointment with your doctor or <u>TB Control Unit</u> for assessment of your symptom/s. Further referral to a TB specialist may be recommended by your doctor. You will require a clearance for signs of active TB from the assessing clinician (doctor or TB Control Unit) to be provided to your Education Provider Placement Coordinator before you can commence a placement: 		
→ Clearance for active TB required □ No □ Yes Clearance for active TB attack	ached 🗆 Yes	
Ple	ease continue over page	





Part B: TB exposure risk history			
1. Were you born in Australia?	🗆 No 🗖 Yes		
If no, in what country were you born?			
 Other than Australia or your country of birth, have you spent three (3) months or more in total within the past five (5) years visiting or living in any other country/ies? (For example, two months in country A and one month in country B is three months in total). 	□ No □ Yes		
If yes, which countries?			
 Check the <u>TB country incidence list (www.health.nsw.gov.au/Infectious/tuberculosis/Pages/high-incidence-countries.aspx)</u> for each country you have listed in questions 1 and 2 and complete the following questions: 			
3. Were you born, and/or have you spent three (3) months or more in total within the past five (5) years visiting or living in country/ies with a TB burden greater than 40 cases per 100 000 population (see link above)?	🗆 No 🗖 Yes		
 Have you been in direct contact with a person with active TB disease, without using appropriate infection control precautions, within the past 2 years and you were not assessed for exposure to TB by hospital or public health authorities (Contact may be work or non-work related). 	🗆 No 🗖 Yes		
5. Have you previously worked (> 3 months) in any of the following settings: respiratory units; infectious disease units or other medical units caring for infectious TB patients; clinical procedure units conducting bronchoscopy and/or sputum induction; TB laboratories; mortuaries?	🗆 No 🗖 Yes		
6. Have you ever been diagnosed with active TB (i.e. not latent TB)?	🗆 No 🗖 Yes		
If yes, in what year did you complete treatment?			
7. Do you have any underlying health issues or take any medications which may cause immunosuppression ?	🗆 No 🗖 Yes		
If you have answered YES to any of questions 3 – 5 from Part B, you require a test for latent TB infection: → an Interferon Gamma Release Assay (IGRA) blood test can be ordered by your doctor – pathology fees may apply (a positive or indeterminate IGRA result requires further consultation at a TB Control Unit or with your doctor. Your doctor may refer you to a TB specialist.			
 OR → a Tuberculin Skin Test (TST/Mantoux test) can be performed by referral to a <u>TB Control Unit</u> – at no cost to the patient, but requires a follow-up appointment 2 or 3 days later. 			
If testing for latent TB infection is required (and you have answered <u>NO</u> to <u>all questions in Part A</u>), you will still be able to commence placement. However, you must undertake further assessment with a doctor or at a TB Control Unit.			
If you have answered YES to any of questions 6 – 7 from Part B, you require further assessment. Contact your TB Control Unit for advice.			
NOTE there is no out-of-pocket expense for treatment of TB in public health facilities in Queensland			
Part C: Previous TB risk assessment procedures: – In the time since encountering the risk factors	in Part B have		
you undergone any assessments or screening as below. If you have previously had a test for later			

unnecessary repetition of testing please take (if available) any supporting documents and additional information as indicated below to your doctor or TB Control Unit.

Previous employment or immigration screening for TB?	□ No □ Yes
Previous TB risk assessment is on SPA (Staff Protect Application-Queensland Health Data Base)	□ No □ Yes
Previous pathology result (Quantiferon test or T-spot test)	□ No □ Yes
Previous printed result of a tuberculin skin test result (also called Mantoux test)	□ No □ Yes

Assessment Summary: Please tick the appropriate TB Risk Assessment Outcomes.

If YES to any questions in Part A clearance for active TB is required prior to placement .	Clearance for active TB attached to Risk Assessment form and returned to your Education Provider Placement Coordinator D.	
If NO to all questions in Part A <u>AND</u> NO to Part B questions 3 to 7 (inclusive)-Nil further assessment required □.	Completed and signed Risk Assessment form returned to your Education Provider Placement Coordinator D.	
If YES to any of questions Part B questions 3 – 7 further testing/consultation with a doctor or consultation at a TB Control Unit is required D .	Completed and signed Risk Assessment form returned to your Education Provider Placement Coordinator . Student consents to undertake assessment with a doctor or at a TB Control Unit .	
TB Control Units Contact Details www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-		

infection/diseases/tuberculosis

Acknowledgement and Consent:

I certify that I have read and understand the <u>Queensland Health: Protocol for the control of tuberculosis</u>— <u>section 3.3.18</u> <u>Workers and students in health care facilities risk assessment</u> on the Queensland Health Clinical Placement website, in preparation for my placement. I agree to comply with the guidelines and all procedures in place at the Queensland Hospital and Health Service facility at which I am placed, in respect of Queensland Health vaccination and infection control of health care workers.

I understand that this risk assessment and any required follow-up action is one of the requirements of eligibility for a placement at a Queensland Hospital and Health Service facility, and I agree to take action as required.

I consent to my education provider giving personal information in this form to Queensland Health (including the Department of Health and Hospital and Health Services) for placement and infection management planning and response. This may include infection control units and TB control units.

I certify that the information I have provided in this risk assessment is true and correct.

Full Name:

Signed:

Date:

Further information and Resources

- Tuberculosis Risk Assessment- Frequently Asked Questions (FAQ) for Workers in Queensland Health Facilities
- Tuberculosis Risk Assessment-Guideline for Education Provider Placement Co-ordinators

Clinician Use Only

Assessment of Tertiary Students for active and latent tuberculosis: Helpful Hints for General Practitioners.

While tuberculosis (TB) is not common in Australia, each year 1200-1300 cases of TB are diagnosed nationally, of which almost 10% are tertiary students and almost 5% are past or current healthcare workers (HCW). The majority of such cases, but not all, are born overseas in countries with much higher rates of TB than we have in Australia.

Queensland Health requires all students who are to undertake placement in a clinical setting to complete a TB risk assessment questionnaire to help identify active TB and latent TB. Those who are identified as being at risk, may present to their GP for further assessment.

There are three main scenarios to consider.

A. Student self-reports symptoms which could be active TB

The symptoms as described on the risk assessment which may prompt a referral for assessment are one or more of the following:

- 1. Cough for more than 2 weeks (not related to an existing diagnosis or condition)
- 2. Unexplained fever for more than 1 week
- 3. Recent unexplained weight loss
- 4. Coughing up blood
- 5. Excessive sweating at night for more than one week.

As prolonged cough and haemoptysis may be features of pulmonary TB, it is recommended that such symptoms be identified at the time of booking-in the patient (if possible), in order that appropriate infection control precautions may be implemented, such as the patient waiting outside until called and the patient wearing a surgical mask when inside the practice (this reduces production of infectious aerosols should the patient actually have TB).

You may prefer to promptly refer your patient to a public TB Control Unit (TBCU) (contact details below) where no further out of pocket expenses will be incurred for the student. Similarly, a referral to a specialist experienced in TB medicine (usually a respiratory physician or infectious diseases physician) may be considered.

Investigations which may be initiated from primary care, if undertaken, should include:

- Three expectorated sputum for "AFBs" (acid fast bacilli) note sputa should be collected external to a GP practice or pathology collection office (away from others) unless appropriate negative pressure facilities are available.
- A CXR (PA and lateral views).

If the CXR is abnormal or sputa are smear or culture positive for TB, referral to a TBCU or a specialist experienced in TB medicine is recommended.

B. Student is asymptomatic but has risk factors that make latent TB more likely

In most cases, it is being born in a country with high TB incidence which makes TB infection more likely, but living in such countries for a prolonged period and working in clinical or laboratory areas with increased potential exposure to TB are also risk factors.

People with latent TB are asymptomatic but they may progress to active TB including infectious pulmonary TB with a lifetime risk of \sim 10%. This risk can be reduced by 80 – 90% by administering antimicrobial therapy for 4 – 9 months (depending on the agent used).

Students with increased risk for latent TB are asked to present to a TBCU or GP for further testing. Latent TB can only be diagnosed by a test which measures immune response to TB proteins; either an interferon-gamma release assay (IGRA) or a tuberculin skin test.

The most practical test in general practice is the QuantiFERON[®] Gold Plus test (IGRA) as it requires a single blood sample, is done by public and private labs and is unaffected by previous BCG vaccination.

A negative IGRA test needs no further action in an asymptomatic student (NOTE: an IGRA test should <u>not</u> be used to exclude active TB as it may be falsely negative).

A student with a positive IGRA test should be counselled regarding the pros and cons of preventative antimicrobial treatment. Active TB should be excluded before treatment for latent TB is commenced. At this point referral to a TBCU or experienced TB clinician can be considered for expert assessment and choice of preventative regimen (usually rifampicin or isoniazid daily therapy). A CXR prior to referral is helpful- if the CXR is abnormal request a priority review.


As Medicare reimbursement for the IGRA is limited and considering that many overseas students may not be Medicare eligible, there is often a charge for this test when ordered privately.

A tuberculin skin test can be performed by a TBCU. It is free of charge, but requires 2 visits to the clinic 48 – 72 hours apart and may be positive due to past BCG vaccination rather than true latent TB.

C. Student is at increased risk of progression to active TB and more severe disease because they have a suppressed immune system

There are many reasons for immune suppressed states including HIV infection, organ transplant anti-rejection drugs, connective tissue diseases etc. Students are asked to identify whether they have an immune suppressing condition. If "yes" they should see their doctor regarding testing for latent TB. A negative test is a useful baseline and a positive test should prompt discussion and offering of preventative antimicrobial therapy.

Additional information including contact details for Queensland TB Control Units can be found on the Queensland Health Tuberculosis Webpage at www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/diseases/tuberculosis



* Infection control guidelines for the management of patients with suspected or confirmed pulmonary tuberculosis in healthcare settings http://www.health.gov.au/internet/main/publishing.nsf/content/cda-cdi4003-pdf-cnt.htm

*Medicare listing for reimbursement of IGRA tests:

Test of cell mediated immune response in blood for the detection of latent tuberculosis by interferon gamma release assay (IGRA) in the following people:

(a) a person who has been exposed to a confirmed case of active tuberculosis;

(b) a person who is infected with human immunodeficiency virus;

- (c) a person who is to commence, or has commenced, tumour necrosis factor (TNF) inhibitor therapy;
- (d) a person who is to commence, or has commenced, renal dialysis;

(e) a person with silicosis;

(f) a person who is, or is about to become, immunosuppressed because of a disease, or a medical treatment, not mentioned in paragraphs (a) to (e).